Tagraxofusp
Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM) [1].
Product Specifications
CAS Number
[2055491-00-2]
Product Name Alternative
SL-401
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tagraxofusp.html
Solubility
10 mM in DMSO
Smiles
[Tagraxofusp]
References & Citations
[1]Ray A, et al. A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells. Leukemia. 2017 Dec;31 (12) :2652-2660.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Isoform
IL-3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
